When it comes to advocating for rheumatology, it’s never too early or late in your career to begin, and no effort is too small to have an impact, says Dr. Ziglar, a private practitioner and member of the Government Affairs Committee.
While an active member of her state rheumatology society, L. Manuela Marinescu, MD, saw the value of connecting with other regional groups to share information and advocacy strategies. On Nov. 16, she assumed the role of chair of the ACR’s Affiliate Society Council (ASC), where she will help facilitate those connections. Dr. Marinescu graduated with…
As his term as chair of the Affiliate Society Council draws to a close, Chris Adams, MD, FACP, FACR, reflects on the personal and professional rewards of volunteer leadership and the importance and impact of coordinated state-level advocacy efforts for the future of rheumatology.
Editor’s note Nov. 23, 2020: As of Nov. 12, 2020, UHC has delayed implementation of the policy discussed below. See “UnitedHealthcare Delays Copay Accumulator Policy.” UnitedHealthcare (UHC) announced that, as of Jan. 1, 2021, providers will be required to report the amount their patients receive in copay assistance for office-administered treatments. UHC will then use…
Attendees at the ACR Convergence session will learn about key regulatory issues affecting rheumatology and how to add their voices to strengthen the ACR’s advocacy efforts.
The COVID-19 pandemic and response disrupted state legislative sessions and agendas in 2020, leaving many ACR priorities unfulfilled and highlighting the urgent need for vocal rheumatology leaders in Washington, D.C., and state capitols.
The ACR, CSRO and Arthritis Foundation asked the Centers for Medicare & Medicaid Services to review the decision to add Stelara to the Self-Administered Drugs list, which would limit access for patients who can’t self-administer.
The ACR is urging insurance companies to expand access to telehealth services and provide relief from administrative burdens to help providers focus on patient care at this critical time.
When insurance company practices put patients at risk, advocacy is an important tool physicians can use to make a real difference. You can make a difference.